| Jun 4 |
BridgeBio data show sustained benefit for achondroplasia drug
|
| Jun 4 |
BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
|
| Jun 3 |
BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
|
| Jun 3 |
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
|
| May 29 |
BridgeBio reports additional positive data for acoramidis in ATTR-CM
|
| May 29 |
Additional Data Showing Acoramidis Increases Serum Transthyretin Which is Associated with Improved Cardiovascular Outcomes Presented at ISA from BridgeBio Pharma’s Phase 3 ATTRibute-CM Study in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
|
| May 27 |
7 Biotech Stocks to Put on Your Breakthrough Radar
|
| May 24 |
BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
|
